Peer Reviewedhttp://deepblue.lib.umich.edu/bitstream/2027.42/109918/1/cptclpt2014183.pd
Although clopidogrel reduces the incidence of atherothrombotic events, its use is associated with an...
Background— We observed that the prodrug clopidogrel was less effective in inhibiting platelet aggre...
ObjectivesThe purpose of this study was to determine the risk of adverse cardiovascular events assoc...
Background: Clopidogrel is a prodrug, the minority of which is converted to an active metabolite by ...
Clopidogrel reduces the cardiovascular risks because of inhibitory action on platelets aggregation b...
Multidrug therapy increases the risk for drug–drug interactions. Clopidogrel, a prodrug, requires he...
Clopidogrel, the top prescribed antiplatelet medication for individuals who have experienced a myoca...
PURPOSE: Clopidogrel is metabolized by the hepatic cytochrome P450 (CYP) system into its active thio...
Introduction: Clopidogrel is an antiplatelet agent that is widely used for the secondary prevention ...
AbstractBackgroundClopidogrel, a prodrug is found to be less effective in inhibiting the platelet ag...
Introduction: Clopidogrel ineffectiveness is a serious problem in antiplatelet therapy. Many factors...
Objective To investigate the effect of clopidogrel gene polymorphism on platelet reactivity and majo...
ObjectivesBecause of the known CYP3A4 inhibition by calcium-channel blockers (CCBs), we hypothesized...
BACKGROUND: Clopidogrel is a prodrug requiring metabolism by cytochrome P450 3A (CYP3A) isoenzymes, ...
textIntroduction: Proton pump inhibitors (PPI) may impair the biotransformation of clopidogrel leadi...
Although clopidogrel reduces the incidence of atherothrombotic events, its use is associated with an...
Background— We observed that the prodrug clopidogrel was less effective in inhibiting platelet aggre...
ObjectivesThe purpose of this study was to determine the risk of adverse cardiovascular events assoc...
Background: Clopidogrel is a prodrug, the minority of which is converted to an active metabolite by ...
Clopidogrel reduces the cardiovascular risks because of inhibitory action on platelets aggregation b...
Multidrug therapy increases the risk for drug–drug interactions. Clopidogrel, a prodrug, requires he...
Clopidogrel, the top prescribed antiplatelet medication for individuals who have experienced a myoca...
PURPOSE: Clopidogrel is metabolized by the hepatic cytochrome P450 (CYP) system into its active thio...
Introduction: Clopidogrel is an antiplatelet agent that is widely used for the secondary prevention ...
AbstractBackgroundClopidogrel, a prodrug is found to be less effective in inhibiting the platelet ag...
Introduction: Clopidogrel ineffectiveness is a serious problem in antiplatelet therapy. Many factors...
Objective To investigate the effect of clopidogrel gene polymorphism on platelet reactivity and majo...
ObjectivesBecause of the known CYP3A4 inhibition by calcium-channel blockers (CCBs), we hypothesized...
BACKGROUND: Clopidogrel is a prodrug requiring metabolism by cytochrome P450 3A (CYP3A) isoenzymes, ...
textIntroduction: Proton pump inhibitors (PPI) may impair the biotransformation of clopidogrel leadi...
Although clopidogrel reduces the incidence of atherothrombotic events, its use is associated with an...
Background— We observed that the prodrug clopidogrel was less effective in inhibiting platelet aggre...
ObjectivesThe purpose of this study was to determine the risk of adverse cardiovascular events assoc...